Future Oncology · 2015 · 17 citations · 26 references
MedicineMolecular MedicineOncologyCancer GeneticsMolecular OncologyNeoplasiaCancer Molecular PathologyLung CancerMalignant NeoplasmsMolecular Classification Of TumorsPulmonary PathologyClinical Outcome MeasurementClinical Outcome ReportingDruggable Target DiscoveryLung AdenocarcinomaLung Cancer PathologyLung CarcinogenesisPulmonary Neuroendocrine TumorsYoung Women
INTRODUCTION: We describe the clinical features, outcome and incidence of druggable targets of lung cancers in patients ≤ 40 years old. MATERIALS & METHODS: Young patients were compared with two other groups (41-64 and ≥ 65 years). Neuroendocrine tumors, adenocarcinoma and non-adenocarcinoma/unspecified non-small-cell lung cancer were analyzed separately. Molecular characteristics of adenocarcinoma were evaluated in a subset of young patients. RESULTS: Of 2847 patients with lung cancer, 100 were ≤ 40 years old. The young group contained more women, never-smokers and patients presenting with advanced disease. The commonest tumor in young patients was adenocarcinoma. In total, 19 of 34 young patients with adenocarcinoma had tumors with specific molecular alterations. CONCLUSION: Lung cancers in young patients have distinctive features but outcomes similar to those in older patients.
26
Revisions in the International System for Staging Lung Cancer
Clifton F. Mountain · CHEST Journal · 1997 · 4.6K citations
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations
Medicine, Oncology, Pharmacology +14
A 5‐decade analysis of 13,715 carcinoid tumors
Irvin M. Modlin, Kevin D. Lye, Mark Kidd · Cancer · 2003 · 2.7K citations
William D. Travis, Walter L. Rush, Douglas B. Flieder et al. · The American Journal of Surgical Pathology · 1998 · 806 citations